Status:
COMPLETED
Dialysis Performance of the FX CorAL Membrane
Lead Sponsor:
University Hospital, Ghent
Conditions:
Hemodialysis Complication
Anticoagulants
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Anticoagulation remains an important issue in the setting of hemodialysis, and up till now there are some major points on which further research is needed. First, it is important to have a portfolio o...
Detailed Description
The FX CorAL is a polysulfone dialyzer with improved biocompatibility due to the increased polyvinylpyrrolidone (PVP) content on its blood side surface. Herewith, protein adsorption onto the membrane ...
Eligibility Criteria
Inclusion
- stable chronic hemodialysis patient
- well functioning vascular access
Exclusion
- known coagulation disorder
- active inflammation
- malignancy
Key Trial Info
Start Date :
October 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06203795
Start Date
October 2 2023
End Date
December 1 2024
Last Update
March 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ghent University Hospital
Ghent, Belgium, 9000